Tirzepatide, marketed as Mounjaro and Zepbound, adds GIP receptor activation to GLP-1 effects
You have to rely on protocol
Contribution statement All authors significantly contributed to the manuscript and approved the final version for publication
and bremelanotide, a melanocortin 4 receptor agonist (NCT06565611)
I believe these medications have such broad effects because a lot of health problems begin with disruptions in insulin resistance [abnormalities in how the body handles glucose] and inflammation, says Jamy Ard, MD, a professor of epidemiology and prevention at Wake Forest University School of Medicine in Winston-Salem, North Carolina
Research has shown positive results, with participants who had obesity and prediabetes losing 12% to 19% of their body weight, depending on dosage